Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Volrustomig · MEDI-5752

Bispecific antibody · Antagonist of PD-1 (PDCD1) and CTLA-4 · developed by ASTRAZENECA

Phase 3 Most advanced trial

AZN Developer

1 Registered trials

What is Volrustomig?

Volrustomig is a bispecific IgG1 monoclonal antibody that binds and blocks both PD-1 and CTLA-4 on tumor-infiltrating T lymphocytes. It inhibits the downregulation of T-cell activation and proliferation, restores immune function, and activates cytotoxic T-lymphocyte responses against tumor cells. It is studied in locally advanced head and neck squamous cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MEDI-5752
Drug type: Bispecific antibody
Targets: PD-1 (PDCD1), CTLA-4
Mechanism: Antagonist of PD-1 (PDCD1) and CTLA-4
Pathways: T-cell activation, immune checkpoint inhibition
Therapy area: Immunology, Oncology
Developer: ASTRAZENECA (AZN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: K96EGJ218N

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06129864	Phase 3	Locally Advanced Head and Neck Squamous Cell Carcinoma	Recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Locally Advanced Head and Neck Squamous Cell Carcinoma

Other drugs acting on PDCD1 / CTLA4

Berahyaluronidase Alfa and Pembrolizumab FDA approved Ipilimumab FDA approved Nivolumab FDA approved Pembrolizumab FDA approved Toripalimab FDA approved Tremelimumab FDA approved Atigotatug/Nivolumab Phase 1 Balstilimab Phase 2/3 Botensilimab Phase 2/3 BPT567 Phase 1 Budigalimab Phase 2/3 Cadonilimab Early Phase 1

More from ASTRAZENECA

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Olaparib FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Volrustomig

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z